Literature DB >> 18550230

Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses.

Choon Kit Tang1, Kuo-Ching Sheng, Dodie Pouniotis, Sandra Esparon, Hye-Youn Son, Chul-Woo Kim, Geoffrey A Pietersz, Vasso Apostolopoulos.   

Abstract

DNA immunization is an attractive form of vaccination, which has shown promising results only in small animal models. There is a need to develop efficient gene delivery systems. We previously demonstrated that oxidized (OM) and reduced mannan (RM) complexed to ovalbumin DNA via poly-l-lysine (PLL), were able to generate potent immune responses in mice. Herein, we further investigated the suitability of OMPLL and RMPLL as carriers for mucin 1 (MUC1) DNA vaccination for cancer immunotherapy. Studies presented here showed that immune responses in C57BL/6 mice induced by OMPLL-MUC1 DNA and RMPLL-MUC1 DNA immunization were more immunogenic compared to MUC1 DNA alone. Moreover, tumor protection was evident at a dose as low as 0.5 microg. In addition, strong T cell responses were induced in HLA-A2 transgenic and human MUC1 transgenic mice. These results demonstrate the potential of OM and RM as efficient non-viral gene delivery carriers for DNA vaccines for use in cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18550230     DOI: 10.1016/j.vaccine.2008.05.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Biomedical Applications of Biodegradable Polymers.

Authors:  Bret D Ulery; Lakshmi S Nair; Cato T Laurencin
Journal:  J Polym Sci B Polym Phys       Date:  2011-06-15

2.  Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.

Authors:  Jie Zhang; Ying Wang; Yang Wu; Zhen-Yu Ding; Xin-Mei Luo; Wu-Ning Zhong; Jie Liu; Xiang-Yu Xia; Guo-Hua Deng; Yao-Tiao Deng; Yu-Quan Wei; Yu Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-14       Impact factor: 4.553

Review 3.  Targeting antigens to dendritic cell receptors for vaccine development.

Authors:  Vasso Apostolopoulos; Theresia Thalhammer; Andreas G Tzakos; Lily Stojanovska
Journal:  J Drug Deliv       Date:  2013-10-08

Review 4.  Dendritic cell immunotherapy: clinical outcomes.

Authors:  Vasso Apostolopoulos; Geoffrey A Pietersz; Anastasios Tsibanis; Annivas Tsikkinis; Lily Stojanovska; Ian Fc McKenzie; Stamatis Vassilaros
Journal:  Clin Transl Immunology       Date:  2014-07-18

5.  The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer.

Authors:  Vanessa Barriga; Nyanbol Kuol; Kulmira Nurgali; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2019-08-19       Impact factor: 6.575

Review 6.  Nanoengineering of vaccines using natural polysaccharides.

Authors:  Ana Sara Cordeiro; María José Alonso; María de la Fuente
Journal:  Biotechnol Adv       Date:  2015-06-03       Impact factor: 14.227

Review 7.  Carbohydrate Conjugates in Vaccine Developments.

Authors:  Shuyao Lang; Xuefei Huang
Journal:  Front Chem       Date:  2020-04-15       Impact factor: 5.221

8.  The Long Road of Immunotherapeutics against Multiple Sclerosis.

Authors:  Vasso Apostolopoulos; Abdolmohamad Rostami; John Matsoukas
Journal:  Brain Sci       Date:  2020-05-11

Review 9.  MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.

Authors:  David Roulois; Marc Grégoire; Jean-François Fonteneau
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

10.  Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.

Authors:  Nicole Brooks; Jennifer Hsu; Sandra Esparon; Dodie Pouniotis; Geoffrey A Pietersz
Journal:  Molecules       Date:  2018-09-02       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.